Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed as an approved prescription medicine. It is marketed under the brand names Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), and is designed for once-daily subcutaneous administration. Its structure is a modified human GLP-1 analog with a fatty-acid chain that promotes reversible binding to albumin, extending its duration relative to native GLP-1.

As with other agents in this class, the approved, regulated products differ from "research" or "for research use only" versions sold outside pharmacy channels. Such vendor material is not the approved medicine, is not subject to the same quality assurance, and should not be considered interchangeable with a prescribed product.

Liraglutide activates the GLP-1 receptor, reproducing key actions of the incretin hormone GLP-1. Described mechanisms include:

• Enhancing glucose-dependent insulin secretion from the pancreas
• Reducing inappropriate glucagon secretion when glucose is elevated
• Slowing gastric emptying to blunt post-meal glucose spikes
• Acting on central appetite pathways to lower hunger and energy intake

Because its insulin effect is glucose-dependent, the class is associated with a comparatively low intrinsic risk of hypoglycemia, though that risk increases when it is combined with insulin or insulin secretagogues.

In regulated medical practice, liraglutide has been approved (depending on jurisdiction and brand) as an adjunct to diet and exercise for glycemic control in type 2 diabetes, and separately for chronic weight management in individuals meeting defined criteria. The two branded products differ in their approved indications and labeling despite sharing the same active molecule.

Liraglutide is a distinct molecule from semaglutide and dulaglutide, with a different dosing frequency and pharmacokinetic profile. Any real-world use should be directed by a qualified clinician and aligned with local regulations and product labeling.

As of publicly available information, liraglutide is not specifically listed as a prohibited substance in sport. Athletes should still verify status against the current WADA Prohibited List and consult their national anti-doping organization, because classifications are reviewed periodically and any medication use may carry separate therapeutic-use considerations.

Gastrointestinal effects are the most commonly described, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These are often most pronounced early in use.

Product labeling for this class carries a boxed warning about thyroid C-cell tumors seen in rodent studies, with human relevance uncertain; the class is generally described as contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis and gallbladder-related events, including gallstones, are also discussed, along with injection-site reactions. Contraindications, monitoring, and overall risk–benefit judgments should be made by a prescribing clinician.

Liraglutide's albumin-binding design gives it a half-life supporting once-daily administration, which differs from once-weekly agents in the class. The approved products follow a structured titration approach intended to improve gastrointestinal tolerability.

This page intentionally avoids specific numbers, schedules, or protocols. Concentration, exposure, and titration are governed by the approved product's labeling and by the prescribing clinician. Any decisions about administration belong within that regulated framework.

The approved medicines are supplied as multi-dose prefilled subcutaneous pens. Liraglutide is also a component of at least one approved fixed-ratio combination with basal insulin in some regions, illustrating class interest in complementary co-formulation.

Any structural or catalog listings are organizational and are not endorsements of specific combinations, sourcing, or use cases; vendor "research" material remains distinct from the approved formulations.

Randomized controlled trials have evaluated liraglutide for glycemic control in type 2 diabetes and for weight management, and dedicated cardiovascular outcome research has examined its effects on major cardiovascular events in relevant populations. Additional studies have explored related metabolic endpoints.

Because the evidence base evolves, this is a high-level snapshot rather than a comprehensive or permanently current review. Clinical and personal decisions should rely on up-to-date primary literature, current labeling, and trusted guidelines.

For deeper dives on this peptide, see:

• Liraglutide benefits and areas of interest
• Liraglutide side effects and safety context
• Liraglutide dosing concepts (educational)
• Liraglutide research and evidence overview

Common high-level questions include how liraglutide differs from once-weekly agents such as semaglutide and dulaglutide, why Victoza and Saxenda share a molecule but not indications, and how clinicians weigh its gastrointestinal effects against its metabolic data. Answers here remain educational and non-prescriptive, and emphasize that approved products differ from any vendor "research" version.